Ziprasidone

• CAT Number: I001784
• CAS Number: 146939-27-7
• Molecular Formula: C21H21ClN4OS
• Molecular Weight: 412.94
• Purity: ≥95%
• Target: 5-HT receptor; Dopamine receptor
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IUPAC Name: 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one
• InChI: InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27)
• InChIKey: MVWVFYHBGMAFLY-UHFFFAOYSA-N
• SMILES: C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54

Ziprasidone (CAT: I001784) is an atypical antipsychotic medication used for the treatment of schizophrenia and bipolar disorder. It belongs to the class of drugs known as second-generation antipsychotics. Ziprasidone works by blocking the action of certain neurotransmitters, including dopamine and serotonin, in the brain. This helps to restore the balance of these chemicals and alleviate the symptoms of psychosis. Ziprasidone has also been studied for its efficacy in the treatment of other psychiatric conditions, such as acute manic or mixed episodes associated with bipolar disorder.

Overview of Clinical Research

Ziprasidone is a dopamine D2 receptor antagonists and serotonin 2 receptor antagonist. Pfizer terminated a phase III six-month extension study in Bipolar disorders (In children, In adolescents) in USA, and decided to perform the pre-specified final analysis at the current enrollment using a re-estimation of the sample size (NCT03768726) in Sep 2020.

Reference

1. Seeger, T.F., et al., Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther, 1995. 275(1): p. 101-13.
2. Prakash, C., et al., Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metab Dispos, 1997. 25(7): p. 863-72.
3. Gao, K., et al., Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia. J Clin Psychopharmacol, 2013. 33(3): p. 425-31.